NCT04564365

Brief Summary

The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 30, 2019

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

September 22, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 25, 2020

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 25, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 25, 2021

Completed
Last Updated

November 11, 2021

Status Verified

June 1, 2021

Enrollment Period

2.4 years

First QC Date

September 22, 2020

Last Update Submit

November 9, 2021

Conditions

Acute Coronary Syndrome

Keywords

left ventricular ejection fractionacute myocardial infarctionbeta-blocker

Outcome Measures

Primary Outcomes (1)

  • mortality

    all-cause mortality

    the median time of 8 months

Study Arms (2)

with beta-blocker

Drug: beta-blocker

without beta-blocker

Interventions

beta-blockerDRUG

To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction

with beta-blocker

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The patient had normal left ventricular ejection fraction (LVEF≥50%) after acute myocardial infarction.

You may qualify if:

  • The diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal

You may not qualify if:

  • History of heart failure Died in hospital

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The first affiliated Hospital of Chongqing Medical University

Chongqing, 400042, China

RECRUITING

MeSH Terms

Conditions

Acute Coronary Syndrome

Interventions

Adrenergic beta-Antagonists

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Adrenergic AntagonistsAdrenergic AgentsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesPhysiological Effects of Drugs

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 22, 2020

First Posted

September 25, 2020

Study Start

June 30, 2019

Primary Completion

November 25, 2021

Study Completion

December 25, 2021

Last Updated

November 11, 2021

Record last verified: 2021-06

Locations

CN(1)